About Us

iTolerance is a privately held preclinical regenerative medicine company developing potentially first-in-class technologies to enable tissue, organoid or cell therapy without the need for life-long immunosuppression. The Company’s immunomodulatory platform technology, iTOL-100, is a synthetic form of the naturally occurring protein, FasL, combined with a synthetic biotin polyethylene glycol, or PEG, microgel (SA-FasL microgel) which induces durable immune tolerance. iTolerance’s iTOL-101 program utilizes allogeneic cadaveric pancreatic islet and is being developed as a potential cure for Type 1 Diabetes. In a pre-clinical non-human primate study, insulin-dependent Diabetes, pancreatic islet cells derived from cadavers co-implanted with iTOL-100 exhibited long-term function with control of blood glucose levels and restoration of insulin secretion without the use of chronic immune suppression. The Company’s  iTOL-102 program, leverages significant advancements in stem cells to derive human pancreatic islets which allows an inexhaustible supply of insulin-producing cells and is being developed as a potential cure for Type 1 Diabetes. Additionally, the Company is developing iTOL-200 for liver cell therapy, iTOL-201 for liver failure and iTOL-401 as a nanoparticle formulation for large organ transplant without the need for life-long immunosuppression.

Our Values